Traglim Duo Tablet 2.5/500 milligrams
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Mothers Pharmaceutical
MFDS item code 201908713 · Approved 2019.12.31
This product's status changed to Expired on 2024.12.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used alongside dietary and exercise therapy to assist with blood sugar control in adults with Type 2 diabetes. It can be administered in cases where blood sugar control is difficult with monotherapy, especially when there has been no prior experience with diabetes medication. Additionally, it can be used in combination with insulin when sufficient blood sugar control has not been achieved with insulin and metformin combination therapy, or to replace the combination of linagliptin and metformin. Furthermore, when blood sugar control is challenging with the maximum dose of metformin in combination with empagliflozin, it can be administered with empagliflozin to enhance blood sugar management. This medication aids in effective blood sugar control for the treatment of diabetes.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, dose increases should be gradual. 1. Patients not currently treated with metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the starting dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The starting dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral hypoglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients Who Must Not Receive This Medicine).
This medication may cause a serious side effect known as lactic acidosis, so caution is required. Lactic acidosis is a rare but fatal metabolic complication that poses a risk, particularly to patients with poor kidney function or heart disease. It should not be administered to individuals allergic to its active ingredients or excipients, patients with Type 1 diabetes, those with severe renal impairment, or patients in acute infection or dehydration states. Pregnant or breastfeeding women should also avoid using this medication. There is a risk of hypoglycemia; therefore, blood sugar needs to be carefully monitored when used together with insulin or sulfonylureas. Patients with impaired kidney function require regular monitoring of kidney function before and during the use of this medication. This medication should be discontinued before and after procedures using iodine-based contrast agents that can cause acute kidney injury. It is also safe to stop using this medication for a period before and after surgery. This medication may lead to pancreatitis and bullous pemphigoid; hence, if continuous severe abdominal pain or blistering skin occurs, immediate consultation with a doctor is necessary. Long-term use can lead to vitamin B12 deficiency, so checking blood levels of vitamin B12 is advisable. The efficacy of this medication may change when taken with other drugs, so all medications being taken should be disclosed to healthcare providers. Elderly patients are at a common risk of reduced kidney function, making dose adjustments and monitoring renal function important. In case of overdose, the risk of lactic acidosis is increased, necessitating immediate treatment at a hospital, and blood dialysis may be required. This medication should be kept out of reach of children and stored in a place that avoids moisture.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that protects it from air and moisture. The storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius, avoiding areas with high moisture.
Bright yellow, oval, biconvex film-coated tablets
60 tablets/PTP - 60 tablets/PTP [(10 tablets/PTP packaging x 6 packs)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Mothers Pharmaceutical
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.